ResurFX

Unlike other fractional technologies, ResurFX™ needs only one pass to be effective, saving you time and protecting the patient’s skin. ResurFX™ uses a 1565 nm fiber laser and a very advanced scanner, which enables you to choose from more than 600 combinations of shape, size and density for optimal treatment.

Photofabulous

For radiant skin that lets you shine Healthy, clear-looking skin is always on-trend. But as we age, our texture and tone can change. Meet Photofabulous- an optimally tailored treatment that

Lumenis and Baring Private Equity Asia to Accelerate Investment in Aesthetics and Vision Verticals Following the Strategic Sale of Lumenis Surgical for $1.07B

Lumenis will refocus and accelerate planned investments to support the development of its fast-growing Aesthetic and Vision businesses, emphasizing R&D, global sales and marketing channels, and business development activities.

Technology

Lumenis® is a global leader in medical lasers and light-based technologies and continuously develops state-of-the-art products that redefine treatment performance. The primary principal behind lasers and light based technologies is selective photothermolysis (abbreviated SPTL) which is the ability to target specific chromophores (light-reactive elements) such as blood, melanin, or water using a specific wavelength or color of laser or light source. In hair removal treatments, for example, the laser targets the hair follicle (melanin chromophore) while leaving the surrounding skin (water chromophore) and blood vessels (hemoglobin chromophore) unharmed.

Fractional Non Ablative

A non-ablative laser generates beams of coherent light using a very narrow range of wavelengths.The light beams selectively target and heat the water chromophore in the skin. As a result the temperature of the tissue rises which stimulates neocollagenesis. There are various forms of non-ablative lasers and they typically have a good water absorption mechanism that impacts the water chromophores but does not cause ablation. Fiber lasers are commonly used for non-ablative treatments. A fiber laser is an optical fiber that is “doped” with elements designed to generate a laser beam at the desired wavelength. Erbium Glass is a typical fiber laser used for this purpose.

Itay Mayer, VP and Managing Director of Lumenis Vision, shares exciting product updates about OptiLight 2.0 and insights into Lumenis’ consumer campaign at VEE 2023

Itay Mayer, Vice President and Managing Director of Lumenis Vision, caught up with Optometry Times® to share an update on the company and its products, which was showcased during the 2023 Vision Expo East meeting in New York, New York.

Service

Lumenis offers a variety of Medical Equipment Repair and Maintenance plans, tailored to meet your individual needs and provide you with an unsurpassed quality, and timely & cost-effective service. Contact us today for your personalized plan

Lumenis is Proud to Support Scars II, the Second International Scar Treatment Conference in Israel

Lumeni Ltd., the world’s largest energy-based medical device company for surgical, aesthetic, and ophthalmic applications, announced that it will again be supporting the International Scar Treatment Conference in Israel, which will be held for the second time in Tel Aviv, on March 21st-22nd, 2018.

Lumenis Celebrates 50 Years of Changing Lives Through Innovation at the American Academy of Dermatology (AAD)

Lumenis Ltd., the world’s largest energy-based medical device company for surgical, aesthetic, and ophthalmic applications, proudly announces its 50th anniversary, which will be celebrated at the American Academy of Dermatology (AAD) Annual Meeting in Orlando, FL from March 3rd – 7th, 2017.

Lumenis to Be Acquired for Approximately $510 Million, $14.00 per Share, in Cash

Lumenis Ltd. (NASDAQ: LMNS), the world’s largest energy-based medical company for surgical, ophthalmology and aesthetic applications, announced today that it has signed a definitive agreement to be acquired by XIO Group for $14.00 per share in cash, for an aggregate purchase price of approximately $510 million.